KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Depreciation and Depletion (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Depreciation and Depletion for 17 consecutive years, with $132.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation and Depletion fell 21.89% to $132.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $621.0 million, a 4.61% decrease, with the full-year FY2025 number at $621.0 million, down 4.61% from a year prior.
  • Depreciation and Depletion was $132.0 million for Q4 2025 at Bristol Myers Squibb, down from $159.0 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $169.0 million in Q4 2024 to a low of $132.0 million in Q4 2025.
  • A 5-year average of $151.4 million and a median of $151.0 million in 2023 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: increased 11.68% in 2022, then fell 21.89% in 2025.
  • Bristol Myers Squibb's Depreciation and Depletion stood at $137.0 million in 2021, then grew by 11.68% to $153.0 million in 2022, then rose by 6.54% to $163.0 million in 2023, then increased by 3.68% to $169.0 million in 2024, then dropped by 21.89% to $132.0 million in 2025.
  • Per Business Quant, the three most recent readings for BMY's Depreciation and Depletion are $132.0 million (Q4 2025), $159.0 million (Q3 2025), and $165.0 million (Q2 2025).